RU2011105409A - Способ лечения атрофической возрастной макулярной дегенерации - Google Patents
Способ лечения атрофической возрастной макулярной дегенерации Download PDFInfo
- Publication number
- RU2011105409A RU2011105409A RU2011105409/15A RU2011105409A RU2011105409A RU 2011105409 A RU2011105409 A RU 2011105409A RU 2011105409/15 A RU2011105409/15 A RU 2011105409/15A RU 2011105409 A RU2011105409 A RU 2011105409A RU 2011105409 A RU2011105409 A RU 2011105409A
- Authority
- RU
- Russia
- Prior art keywords
- drug delivery
- delivery system
- use according
- dry
- eye
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 3
- 206010064930 age-related macular degeneration Diseases 0.000 title 1
- 208000002780 macular degeneration Diseases 0.000 title 1
- 238000012377 drug delivery Methods 0.000 claims abstract 27
- 239000003795 chemical substances by application Substances 0.000 claims abstract 14
- 229960000397 bevacizumab Drugs 0.000 claims abstract 8
- 229920000642 polymer Polymers 0.000 claims abstract 8
- 238000002347 injection Methods 0.000 claims abstract 6
- 239000007924 injection Substances 0.000 claims abstract 6
- 150000002148 esters Chemical class 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 claims abstract 2
- 102100030289 Chronophin Human genes 0.000 claims abstract 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims abstract 2
- 101150062722 PDXP gene Proteins 0.000 claims abstract 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims abstract 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract 2
- 229920001577 copolymer Polymers 0.000 claims abstract 2
- 230000007850 degeneration Effects 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims abstract 2
- 229960003407 pegaptanib Drugs 0.000 claims abstract 2
- 229960003876 ranibizumab Drugs 0.000 claims abstract 2
- 239000004066 vascular targeting agent Substances 0.000 claims abstract 2
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
1. Биосовместимая система доставки лекарственного средства, содержащая антинеоваскулярный агент, представляющий собой антиваскулярный агент фактора роста эндотелия сосудов (анти-ФРЭС), выбранный из группы, состоящей из бевацизумаба, ранибизумаба и пегаптаниба и их производных, сложных эфиров, солей и смесей, и полимерный носитель, ассоциированный с антинеоваскулярным агентом, где полимерный носитель представляет собой сополимер молочной и гликолевой кислот (ПЛГП), для применения в способе лечения сухой возрастной дегенерации желтого пятна (сухая ВДЖП), включающем этап введения системы доставки лекарственного средства в глаз пациента с сухой ВДЖП, таким образом вылечивая сухую ВДЖП. ! 2. Система доставки лекарственного средства для применения по п.1, где антинеоваскулярный агент ассоциирован с полимерным носителем, будучи диспергирован гомогенно в полимерном носителе. ! 3. Система доставки лекарственного средства для применения по п.1, где этап введения выполняют посредством инъекции антинеоваскулярного агента внутрь передней области глаза. ! 4. Система доставки лекарственного средства для применения по п.1, где этап введения выполняют посредством инъекции антинеоваскулярного агента внутрь задней области глаза. ! 5. Система доставки лекарственного средства для применения по п.4, где этап введения выполняют посредством инъекции антинеоваскулярного агента в полость стекловидного тела. ! 6. Система доставки лекарственного средства для применения по п.1, где антинеоваскулярный агент представляет собой бевацизумаб или его производное, сложный эфир или соль. ! 7. Система доставки лекарственного средства для п
Claims (14)
1. Биосовместимая система доставки лекарственного средства, содержащая антинеоваскулярный агент, представляющий собой антиваскулярный агент фактора роста эндотелия сосудов (анти-ФРЭС), выбранный из группы, состоящей из бевацизумаба, ранибизумаба и пегаптаниба и их производных, сложных эфиров, солей и смесей, и полимерный носитель, ассоциированный с антинеоваскулярным агентом, где полимерный носитель представляет собой сополимер молочной и гликолевой кислот (ПЛГП), для применения в способе лечения сухой возрастной дегенерации желтого пятна (сухая ВДЖП), включающем этап введения системы доставки лекарственного средства в глаз пациента с сухой ВДЖП, таким образом вылечивая сухую ВДЖП.
2. Система доставки лекарственного средства для применения по п.1, где антинеоваскулярный агент ассоциирован с полимерным носителем, будучи диспергирован гомогенно в полимерном носителе.
3. Система доставки лекарственного средства для применения по п.1, где этап введения выполняют посредством инъекции антинеоваскулярного агента внутрь передней области глаза.
4. Система доставки лекарственного средства для применения по п.1, где этап введения выполняют посредством инъекции антинеоваскулярного агента внутрь задней области глаза.
5. Система доставки лекарственного средства для применения по п.4, где этап введения выполняют посредством инъекции антинеоваскулярного агента в полость стекловидного тела.
6. Система доставки лекарственного средства для применения по п.1, где антинеоваскулярный агент представляет собой бевацизумаб или его производное, сложный эфир или соль.
7. Система доставки лекарственного средства для применения по п.6, где система доставки лекарственного средства содержит от приблизительно 5 мкг до приблизительно 3 мг бевацизумаба.
8. Система доставки лекарственного средства для применения по п.7, где система доставки лекарственного средства высвобождает в среднем от приблизительно 10 нг до приблизительно 40 мкг бевацизумаба в течение периода 24 ч, предпочтительно в среднем от приблизительно 14 мкг до приблизительно 28 мкг бевацизумаба в течение периода 24 ч, более предпочтительно в среднем от приблизительно 7 мкг до приблизительно 14 мкг бевацизумаба в течение периода 24 ч.
9. Система доставки лекарственного средства для применения по п.1, где у пациента в одном глазу сухая ВДЖП, а в другом глазу влажная ВДЖП.
10. Система доставки лекарственного средства для применения по п.9, где сухую ВДЖП вылечивают посредством предотвращения или замедления развития сухой ВДЖП во влажную ВДЖП в обработанном глазу.
11. Система доставки лекарственного средства для применения по п.9, где сухую ВДЖП вылечивают посредством предупреждения или замедления возникновения неоваскуляризации сетчатки в инъецированном глазу с сухой ВДЖП.
12. Система доставки лекарственного средства для применения по п.1, где система доставки лекарственного средства имеет вязкость от приблизительно 130000 сПз до приблизительно 300000 сПз при скорости сдвига приблизительно 0,1/с при приблизительно 25°С.
13. Система доставки лекарственного средства для применения по п.1, где система доставки лекарственного средства инъецирована при помощи 25-30 мерного шприца.
14. Система доставки лекарственного средства для применения по п.1, где систему вводят во внутриглазную область, выбранную из группы внутриглазных областей, состоящей из субтеноновой, субконъюнктивальной, супрахориоидальной, интрасклеральной, интравитреальной и ретробульбарной внутриглазных областей.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/176,238 | 2008-07-18 | ||
US12/176,238 US8821870B2 (en) | 2008-07-18 | 2008-07-18 | Method for treating atrophic age related macular degeneration |
PCT/US2009/050373 WO2010009034A2 (en) | 2008-07-18 | 2009-07-13 | Method for treating atrophic age related macular degeneration |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014115647A Division RU2668371C2 (ru) | 2008-07-18 | 2009-07-13 | Способ лечения атрофической возрастной макулярной дегенерации |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2011105409A true RU2011105409A (ru) | 2012-08-27 |
RU2521338C2 RU2521338C2 (ru) | 2014-06-27 |
RU2521338C9 RU2521338C9 (ru) | 2014-09-10 |
Family
ID=41530477
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014115647A RU2668371C2 (ru) | 2008-07-18 | 2009-07-13 | Способ лечения атрофической возрастной макулярной дегенерации |
RU2011105409/15A RU2521338C9 (ru) | 2008-07-18 | 2009-07-13 | Способ лечения атрофической возрастной макулярной дегенерации |
RU2018133133A RU2018133133A (ru) | 2008-07-18 | 2018-09-19 | Способ лечения атрофической возрастной макулярной дегенерации |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014115647A RU2668371C2 (ru) | 2008-07-18 | 2009-07-13 | Способ лечения атрофической возрастной макулярной дегенерации |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2018133133A RU2018133133A (ru) | 2008-07-18 | 2018-09-19 | Способ лечения атрофической возрастной макулярной дегенерации |
Country Status (11)
Country | Link |
---|---|
US (3) | US8821870B2 (ru) |
EP (4) | EP2307055B1 (ru) |
JP (3) | JP2011528656A (ru) |
KR (1) | KR20110047196A (ru) |
CN (2) | CN107412778A (ru) |
AU (1) | AU2009271168B2 (ru) |
BR (1) | BRPI0915981A2 (ru) |
CA (1) | CA2731270C (ru) |
ES (3) | ES2897560T3 (ru) |
RU (3) | RU2668371C2 (ru) |
WO (1) | WO2010009034A2 (ru) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090148527A1 (en) * | 2007-12-07 | 2009-06-11 | Robinson Michael R | Intraocular formulation |
US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
US8197435B2 (en) | 2006-05-02 | 2012-06-12 | Emory University | Methods and devices for drug delivery to ocular tissue using microneedle |
US8039010B2 (en) | 2006-11-03 | 2011-10-18 | Allergan, Inc. | Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
EP2391419B1 (en) | 2009-01-29 | 2019-06-12 | ForSight Vision4, Inc. | Posterior segment drug delivery |
US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
EP2482804A1 (en) * | 2009-10-01 | 2012-08-08 | Evonik Degussa Corporation | Microparticle compositions and methods for treating age-related macular degeneration |
DK2524693T3 (da) * | 2010-01-14 | 2014-08-25 | Sanwa Kagaku Kenkyusho Co | Lægemiddel til forebyggelse eller behandling af lidelser ledsaget af okulær angiogenese og / eller forøget okulær vaskulær permeabilitet |
US20130210876A1 (en) * | 2010-01-21 | 2013-08-15 | Allergan, Inc | Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect |
KR20120125305A (ko) * | 2010-01-21 | 2012-11-14 | 알러간, 인코포레이티드 | 장기 지속 안압 강하 효과를 지니는 알파?2 아드레날린 작용제 |
WO2011137363A1 (en) | 2010-04-30 | 2011-11-03 | Allergan, Inc. | Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase |
PT2600812T (pt) | 2010-08-05 | 2021-11-09 | Forsight Vision4 Inc | Aparelho para tratar um olho |
AU2011285545B2 (en) | 2010-08-05 | 2014-03-13 | Forsight Vision4, Inc. | Injector apparatus and method for drug delivery |
JP6111194B2 (ja) | 2010-08-05 | 2017-04-05 | フォーサイト・ビジョン フォー・インコーポレーテッド | 組み合わせ薬物送達方法および装置 |
MX2013001870A (es) * | 2010-08-17 | 2013-07-03 | Ohr Pharmaceutical Inc | Formulaciones oftalmicas de escualamina. |
JP5996544B2 (ja) | 2010-10-15 | 2016-09-21 | クリアサイド・バイオメディカル・インコーポレーテッドClearside Biomedical Incorporated | 眼球アクセス用装置 |
EP2640360A2 (en) | 2010-11-19 | 2013-09-25 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
JPWO2012105610A1 (ja) * | 2011-02-02 | 2014-07-03 | 株式会社三和化学研究所 | 眼内血管新生及び/又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬 |
US20120276186A1 (en) | 2011-04-29 | 2012-11-01 | Ghebremeskel Alazar N | Sustained release latanoprost implant |
SI2717914T1 (sl) * | 2011-06-10 | 2020-07-31 | Ramscor Inc. | Formulacije z zadržanim sproščanjem za dostavo proteinov v oko in postopki njihove priprave |
EP2720722A4 (en) | 2011-06-16 | 2014-12-03 | Univ Hong Kong Science & Techn | MOLECULAR WITH SEVERAL VINYL SULPHONES |
EP4249059A3 (en) | 2011-06-28 | 2023-11-29 | ForSight Vision4, Inc. | An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye |
CA2872047A1 (en) * | 2011-07-19 | 2013-01-24 | Wilfred Jefferies | Maintenance of cerebral vessel tight junctions and blood-brain barrier integrity to treat or prevent alzheimer's disease |
EP2739252A4 (en) | 2011-08-05 | 2015-08-12 | Forsight Vision4 Inc | SMALL MOLECULE ADMINISTRATION USING AN IMPLANTABLE THERAPEUTIC DEVICE |
HUE054578T2 (hu) | 2011-09-16 | 2021-09-28 | Forsight Vision4 Inc | Fluidumcserélõ berendezés |
US20130156766A1 (en) * | 2011-11-15 | 2013-06-20 | Allergan, Inc. | Treatment of dry age related macular degeneration |
RU2676102C2 (ru) * | 2012-09-27 | 2018-12-26 | Аллерган, Инк. | Биодеградируемые системы доставки лекарственных средств для долговременного высвобождения белков |
CN104884049A (zh) | 2012-11-08 | 2015-09-02 | 克莱尔塞德生物医学股份有限公司 | 用于在人类受试者中治疗眼部疾病的方法和装置 |
CN102988301A (zh) * | 2012-12-26 | 2013-03-27 | 温州医学院 | 一种含贝伐单抗的长效缓释微球的制备方法 |
WO2014152959A1 (en) | 2013-03-14 | 2014-09-25 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
US9254409B2 (en) | 2013-03-14 | 2016-02-09 | Icon Health & Fitness, Inc. | Strength training apparatus with flywheel and related methods |
MX2015015282A (es) | 2013-05-03 | 2016-02-26 | Clearside Biomedical Inc | Aparatos y metodos para inyeccion ocular. |
US10188550B2 (en) | 2013-06-03 | 2019-01-29 | Clearside Biomedical, Inc. | Apparatus and methods for drug delivery using multiple reservoirs |
US20160166701A1 (en) * | 2013-07-05 | 2016-06-16 | Therakine Biodelivery Gmbh | Delivery composition for topical applications and injections and ophthalmic formulations, methods for manufacturing thereof, and methods for delivery of a drug-delivery composition |
US9782345B2 (en) | 2013-10-17 | 2017-10-10 | Jade Therapeutics, Inc. | Ocular composition and method |
EP3071181B1 (en) * | 2013-11-18 | 2021-03-24 | Formycon AG | Pharmaceutical composition of an anti-vegf antibody |
EP3623020B1 (en) | 2013-12-26 | 2024-05-01 | iFIT Inc. | Magnetic resistance mechanism in a cable machine |
CN106470739B (zh) | 2014-06-09 | 2019-06-21 | 爱康保健健身有限公司 | 并入跑步机的缆索系统 |
MX2016017028A (es) | 2014-06-20 | 2017-08-07 | Clearside Biomedical Inc | Canula de diametro variable y metodos para el control de la profundidad de insercion para administracion de medicamentos. |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
EP3177289A4 (en) | 2014-08-08 | 2018-03-21 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
USD750223S1 (en) | 2014-10-14 | 2016-02-23 | Clearside Biomedical, Inc. | Medical injector for ocular injection |
EP3261630A4 (en) * | 2015-02-26 | 2018-10-10 | Feramda Ltd. | Compositions and combinations for the treatment of angiogenesis diseases and disorders |
ES2584534B1 (es) * | 2015-03-27 | 2017-03-13 | Retinset, S.L. | Formulación tópica oftálmica de bosentan |
AU2016241499B2 (en) | 2015-03-31 | 2020-12-17 | Ildong Pharm Co., Ltd. | Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused |
US11253540B2 (en) | 2015-05-29 | 2022-02-22 | Seikagaku Corporation | Composition including glycosaminoglycan derivative and chemokine receptor activity regulator |
US10940360B2 (en) | 2015-08-26 | 2021-03-09 | Icon Health & Fitness, Inc. | Strength exercise mechanisms |
US10953305B2 (en) | 2015-08-26 | 2021-03-23 | Icon Health & Fitness, Inc. | Strength exercise mechanisms |
TWI799366B (zh) | 2015-09-15 | 2023-04-21 | 美商建南德克公司 | 胱胺酸結骨架平臺 |
SG10201911226QA (en) | 2015-09-23 | 2020-01-30 | Genentech Inc | Optimized variants of anti-vegf antibodies |
CN108712911A (zh) | 2015-12-30 | 2018-10-26 | 科达制药股份有限公司 | 抗体及其缀合物 |
US20210353823A9 (en) * | 2016-02-08 | 2021-11-18 | The Johns Hopkins University | Dendrimer-bioadhesive polymer hydrogel nanoglue and use thereof |
US10390901B2 (en) | 2016-02-10 | 2019-08-27 | Clearside Biomedical, Inc. | Ocular injection kit, packaging, and methods of use |
CN115951066A (zh) * | 2016-02-29 | 2023-04-11 | 麦恩泰科特有限公司 | 可用于治疗湿性年龄相关性黄斑变性的预测性标志物 |
JP6664115B2 (ja) * | 2016-03-15 | 2020-03-13 | 原 英彰 | アフリベルセプトによる網膜保護作用 |
US10293211B2 (en) | 2016-03-18 | 2019-05-21 | Icon Health & Fitness, Inc. | Coordinated weight selection |
US10441840B2 (en) | 2016-03-18 | 2019-10-15 | Icon Health & Fitness, Inc. | Collapsible strength exercise machine |
EP3452165A1 (en) | 2016-05-02 | 2019-03-13 | Clearside Biomedical, Inc. | Systems and methods for ocular drug delivery |
US10252109B2 (en) | 2016-05-13 | 2019-04-09 | Icon Health & Fitness, Inc. | Weight platform treadmill |
JP6944958B2 (ja) | 2016-05-25 | 2021-10-06 | 参天製薬株式会社 | 持続性浮腫を伴う滲出性加齢黄斑変性の処置のためのシロリムスの使用 |
CN110177527B (zh) | 2016-08-12 | 2022-02-01 | 科尼尔赛德生物医学公司 | 用于调节药剂递送用针的插入深度的装置和方法 |
US10661114B2 (en) | 2016-11-01 | 2020-05-26 | Icon Health & Fitness, Inc. | Body weight lift mechanism on treadmill |
US11123411B2 (en) * | 2016-12-08 | 2021-09-21 | Gary E. Borodic | Method of treating macular degeneration using botulinum toxin-based pharmaceuticals |
RU2661621C2 (ru) * | 2016-12-19 | 2018-07-17 | Александр Николаевич Епихин | Способ пролонгации и усиления терапевтического эффекта действия ингибиторов ангиогенеза при лечении неоваскулярных форм макулярных дегенераций |
AU2018240375C1 (en) | 2017-03-22 | 2024-02-01 | Ascendis Pharma A/S | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods |
WO2018201007A2 (en) | 2017-04-27 | 2018-11-01 | The Johns Hopkins University | Dendrimer compositions for use in angiography |
KR102101969B1 (ko) * | 2017-09-06 | 2020-04-22 | (주)인벤티지랩 | 목시덱틴을 포함하는 마이크로 입자 및 이의 제조 방법 |
CN111615528A (zh) | 2017-11-10 | 2020-09-01 | 约翰霍普金斯大学 | 树枝状聚合物递送系统和其使用方法 |
WO2019103906A1 (en) | 2017-11-21 | 2019-05-31 | Forsight Vision4, Inc. | Fluid exchange apparatus for expandable port delivery system and methods of use |
CN108030783A (zh) * | 2017-12-27 | 2018-05-15 | 广东众生药业股份有限公司 | 乐伐替尼在制备防治黄斑变性的药物中的用途 |
CN112543645A (zh) * | 2018-04-17 | 2021-03-23 | 前瞻疗法公司 | 用于治疗疾病的贝伐珠单抗的缓冲制剂 |
KR102192768B1 (ko) * | 2018-12-07 | 2020-12-18 | 전북대학교산학협력단 | 식나무 추출물을 포함하는 황반변성의 예방 또는 치료용 약학적 조성물 |
DE102019112917B4 (de) * | 2019-05-16 | 2021-07-22 | Carl Zeiss Meditec Ag | Ophthalmologisches Implantat zur Verwendung bei der Behandlung einer Augenkrankheit und Implantationswerkzeug mit einem solchen ophthalmologischen Implantat |
CN109966243A (zh) * | 2019-05-17 | 2019-07-05 | 上海第二工业大学 | 一种用于眼底黄斑治疗的释药型凝胶及其制备方法 |
GB2601922B (en) | 2019-06-27 | 2024-04-24 | Layerbio Inc | Ocular device drub delivery systems |
AU2020308909A1 (en) * | 2019-06-27 | 2022-01-27 | University Of Florida Research Foundation, Incorporated | Enhancing AAV-mediated transduction of ocular tissues with hyaluronic acid |
US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
JP7451732B2 (ja) | 2020-02-06 | 2024-03-18 | オキュラ セラピューティクス,インコーポレイテッド | 眼疾患を治療するための組成物及び方法 |
BR112022018815A2 (pt) | 2020-03-25 | 2022-11-29 | Ocular Therapeutix Inc | Implante ocular contendo um inibidor de tirosina cinase |
US20240058308A1 (en) * | 2021-01-12 | 2024-02-22 | The Regents Of The University Of Michigan | Treatment and prevention of dry macular degeneration |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2446405A (en) | 1945-10-31 | 1948-08-03 | Hazeltine Research Inc | Tunable ultra high frequency resonator system |
US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
US5264188A (en) * | 1991-01-22 | 1993-11-23 | Phillips Petroleum Company | Multi-stage hydrotreating process and apparatus |
US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
DE60039416D1 (de) * | 1999-02-08 | 2008-08-21 | Human Genome Sciences Inc | Verwendung vom vaskulären endothelialen wachstumsfaktor 2 (vegf-2) |
US7582311B1 (en) * | 1999-10-15 | 2009-09-01 | Genentech, Inc. | Injection vehicle for polymer-based formulations |
ES2240180T3 (es) * | 1999-10-21 | 2005-10-16 | Alcon Inc. | Administracion sub-tenon de medicamentos. |
US20040229960A1 (en) | 2001-07-13 | 2004-11-18 | David Sherris | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
RU2354398C2 (ru) * | 2001-07-13 | 2009-05-10 | Оксиджин, Инк. | Композиции и способы введения средств, связывающих тубулин, для лечения глазных заболеваний |
TWI282271B (en) * | 2002-09-18 | 2007-06-11 | Allergan Inc | Apparatus for delivery of ocular implants |
JP2006508950A (ja) * | 2002-10-31 | 2006-03-16 | セルジーン・コーポレーション | 黄斑変性の治療用組成物 |
US20050101582A1 (en) * | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
US7993634B2 (en) * | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
US7799336B2 (en) * | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US7589057B2 (en) * | 2004-04-30 | 2009-09-15 | Allergan, Inc. | Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems |
US8425929B2 (en) * | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
US8591885B2 (en) | 2004-04-30 | 2013-11-26 | Allergan, Inc. | Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems |
US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
US20060182781A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid contraining microparticles |
US20050244471A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Estradiol derivative and estratopone containing sustained release intraocular implants and related methods |
US20070059336A1 (en) | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
WO2005110374A1 (en) | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
US8722097B2 (en) * | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
WO2006043965A1 (en) * | 2004-10-14 | 2006-04-27 | Allergan, Inc. | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods |
KR20070104931A (ko) * | 2005-02-09 | 2007-10-29 | 마커사이트, 인코포레이티드 | 안구 치료용 제제 |
WO2006110487A1 (en) * | 2005-04-08 | 2006-10-19 | Surmodics, Inc. | Sustained release implants for subretinal delivery |
PT2447283E (pt) * | 2005-09-07 | 2015-10-08 | Pfizer | Anticorpos monoclonais humanos para cinase-1 tipo recetor de activina (alk-1) |
US8168584B2 (en) * | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
EP1959925B1 (en) | 2005-12-02 | 2016-11-23 | (OSI) Eyetech, Inc. | Controlled release microparticles |
US20090221684A1 (en) * | 2005-12-22 | 2009-09-03 | Trustees Of Boston University | Molecules for Gene Delivery and Gene Therapy, and Methods of Use Thereof |
JP2009524684A (ja) * | 2006-01-26 | 2009-07-02 | アキュセラ, インコーポレイテッド | 眼疾患および障害の治療のための組成物および方法 |
US20090285826A1 (en) | 2006-05-04 | 2009-11-19 | Fovea Pharmaceuticals Sa | Combination drugs comprising vegf inhibitor and serine proteases/thrombolytic compounds for treating neovascular disorders |
CN101568332A (zh) * | 2006-08-31 | 2009-10-28 | 阿布拉科斯生物科学公司 | 抑制血管生成及治疗血管生成相关疾病的方法 |
AU2007323925A1 (en) | 2006-11-10 | 2008-05-29 | Genentech, Inc. | Method for treating age-related macular degeneration |
SG173409A1 (en) * | 2006-11-24 | 2011-08-29 | Ac Immune Sa | N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers |
US20080125377A1 (en) * | 2006-11-28 | 2008-05-29 | Bartels Stephen P | Delivery system for antiangiogenic and antiinflammatory pharmaceuticals and method of use |
US8969415B2 (en) * | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
US11078262B2 (en) * | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
CA2968112A1 (en) | 2016-05-26 | 2017-11-26 | Op-Hygiene Ip Gmbh | Dispenser servicing in a multiple washroom facility |
US11461843B2 (en) | 2019-05-23 | 2022-10-04 | Capital One Services, Llc | Multi-lender platform that securely stores proprietary information for pre-qualifying an applicant |
-
2008
- 2008-07-18 US US12/176,238 patent/US8821870B2/en active Active
-
2009
- 2009-07-13 CN CN201611271046.2A patent/CN107412778A/zh active Pending
- 2009-07-13 ES ES19161922T patent/ES2897560T3/es active Active
- 2009-07-13 AU AU2009271168A patent/AU2009271168B2/en not_active Ceased
- 2009-07-13 KR KR1020117003673A patent/KR20110047196A/ko active Search and Examination
- 2009-07-13 WO PCT/US2009/050373 patent/WO2010009034A2/en active Application Filing
- 2009-07-13 RU RU2014115647A patent/RU2668371C2/ru active
- 2009-07-13 CN CN2009801368268A patent/CN102159246A/zh active Pending
- 2009-07-13 BR BRPI0915981-9A patent/BRPI0915981A2/pt not_active Application Discontinuation
- 2009-07-13 EP EP09790328.0A patent/EP2307055B1/en active Active
- 2009-07-13 ES ES13179231T patent/ES2720882T3/es active Active
- 2009-07-13 EP EP13179231.9A patent/EP2664347B1/en active Active
- 2009-07-13 CA CA2731270A patent/CA2731270C/en not_active Expired - Fee Related
- 2009-07-13 ES ES09790328.0T patent/ES2574706T3/es active Active
- 2009-07-13 EP EP19161922.0A patent/EP3524270B1/en active Active
- 2009-07-13 RU RU2011105409/15A patent/RU2521338C9/ru active
- 2009-07-13 JP JP2011518816A patent/JP2011528656A/ja active Pending
- 2009-07-13 EP EP21196540.5A patent/EP3950002A1/en not_active Withdrawn
-
2014
- 2014-07-07 US US14/324,630 patent/US10363214B2/en active Active
- 2014-08-22 JP JP2014169846A patent/JP6009511B2/ja not_active Expired - Fee Related
-
2016
- 2016-06-23 JP JP2016124732A patent/JP6132964B2/ja not_active Expired - Fee Related
-
2018
- 2018-09-19 RU RU2018133133A patent/RU2018133133A/ru not_active Application Discontinuation
-
2019
- 2019-07-19 US US16/516,411 patent/US20190336441A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2011105409A (ru) | Способ лечения атрофической возрастной макулярной дегенерации | |
JP6700348B2 (ja) | 持続型薬物送達インプラント | |
Wang et al. | Injectable hydrogels for ophthalmic applications | |
JP6980671B2 (ja) | 眼科用組成物 | |
JP2011528656A5 (ru) | ||
JP2007535552A5 (ru) | ||
Lee et al. | Novel drug delivery systems for retinal diseases: a review | |
CN101269220B (zh) | 白芨胶为载体的雷帕霉素眼内植入型释药系统 | |
US20230302156A1 (en) | Redox-responsive nanoparticle compositions for ocular delivery of therapeutics | |
Mittal et al. | Recent advancemnts in biodegradable ocular implants | |
JP2013523748A5 (ru) | ||
Ianchulev | Suprachoroidal space as a therapeutic target | |
CN104958762B (zh) | 一种33g针头注射用雷珠单抗眼玻璃体腔内缓释药物 | |
Akulo et al. | Intravitreal Injectable Hydrogels for Sustained Drug Delivery in Glaucoma Treatment and Therapy. Polymers 2022, 14, 2359 | |
CN104667287B (zh) | 用于治疗眼后房新生血管增生的眼用组合物及其用途 | |
RU2020136835A (ru) | Способы и композиции для непрерывного высвобождения микрочастиц для доставки лекарственного средства в ткани глаза | |
Hashem et al. | Subconjunctival bevacizumab, a potential therapeutic strategy for treatment of corneal neovascularization. | |
Belfort et al. | Ozurdex®, a Novel Dexamethasone Delivery System, for Treatment of Macular Edema Following Retinal Vein Occlusion | |
JP2003342166A (ja) | 眼内疾患用製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TH4A | Reissue of patent specification | ||
TK4A | Correction to the publication in the bulletin (patent) |
Free format text: AMENDMENT TO CHAPTER -FG4A- IN JOURNAL: 18-2014 |